Detalhe da pesquisa
1.
A first-in-man safety and pharmacokinetics study of nangibotide, a new modulator of innate immune response through TREM-1 receptor inhibition.
Br J Clin Pharmacol
; 84(10): 2270-2279, 2018 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-29885068
2.
Prospective evaluation of the efficacy, safety, and optimal biomarker enrichment strategy for nangibotide, a TREM-1 inhibitor, in patients with septic shock (ASTONISH): a double-blind, randomised, controlled, phase 2b trial.
Lancet Respir Med
; 11(10): 894-904, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37269870
3.
Evaluation of the efficacy and safety of TREM-1 inhibition with nangibotide in patients with COVID-19 receiving respiratory support: the ESSENTIAL randomised, double-blind trial.
EClinicalMedicine
; 60: 102013, 2023 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-37350989
4.
Rationale and protocol for the efficacy, safety and tolerability of nangibotide in patients with septic shock (ASTONISH) phase IIb randomised controlled trial.
BMJ Open
; 11(7): e042921, 2021 07 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-34233965
5.
Nangibotide in patients with septic shock: a Phase 2a randomized controlled clinical trial.
Intensive Care Med
; 46(7): 1425-1437, 2020 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-32468087
6.
sTREM-1 is a specific biomarker of TREM-1 pathway activation.
Cell Mol Immunol
; 18(8): 2054-2056, 2021 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-34282296